Home
Issues
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
2021
December - Vol 14, No 4
September - Vol 14 No 3
June - Vol 14, No 2
March - Vol 14 No 1
2020
October/November - Vol 13 No 5
September - Vol 13 No 4
June - Vol 13 No 3
May - Vol 13 No 2
February - Vol 13 No 1
Issue Archive
Value-Based Care in Cardiometabolic Health
Special Issues
2021 Special Issues
December - Twelfth Annual Payers' Guide
August - Vol 14, Special Issue: Payers' Perspectives in Oncology
February - Vol 14, Special Issue: Payers' Perspectives in Oncology
2020 Special Issues
Supplements
Special Issue Archive
Topics
Conference Correspondent
ASCO 2020 - Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
2021
December - Vol 14, No 4
September - Vol 14 No 3
June - Vol 14, No 2
March - Vol 14 No 1
2020
October/November - Vol 13 No 5
September - Vol 13 No 4
June - Vol 13 No 3
May - Vol 13 No 2
February - Vol 13 No 1
Issue Archive
Value-Based Care in Cardiometabolic Health
Special Issues
2021 Special Issues
December - Twelfth Annual Payers' Guide
August - Vol 14, Special Issue: Payers' Perspectives in Oncology
February - Vol 14, Special Issue: Payers' Perspectives in Oncology
2020 Special Issues
Supplements
Special Issue Archive
Topics
Conference Correspondent
ASCO 2020 - Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Loretta Fala
Medical Writer
Medical writer
Authored Items
Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Ukoniq (Umbralisib) FDA Approved for Adults with Relapsed or Refractory Marginal-Zone Lymphoma or Follicular Lymphoman
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Skyrizi (Risankizumab-rzaa) a New Treatment Option Approved by the FDA for Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Balversa (Erdafitinib), First-in-Class FGFR Kinase Inhibitor, Approved for Patients with Metastatic Urothelial Carcinoma and FGFR Mutations
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Spravato (Esketamine) Nasal Spray First NMDA Receptor Antagonist Approved by the FDA for Adults with Treatment-Resistant Depression
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Cablivi (Caplacizumab-yhdp): First Targeted, Nanobody-Based Therapy Approved for Adults with Acquired Thrombotic Thrombocytopenic Purpura
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Tremfya (Guselkumab), a Novel One-Press Patient-Controlled Injection, Approved for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Doptelet (Avatrombopag) Receives FDA Approval for the Treatment of Patients with Chronic Immune Thrombocytopenia
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Zulresso (Brexanolone) First Drug Approved by the FDA Specifically for Postpartum Depression in Adults
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
Select Drug Profiles
Tavalisse (Fostamatinib Disodium Hexahydrate) First Spleen Tyrosine Kinase Inhibitor Approved for Chronic Immune Thrombocytopenia
Loretta Fala
Web Exclusives
in
Select Drug Profiles
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Loretta Fala
Web Exclusives
in
Select Drug Profiles
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Loretta Fala
Web Exclusives
in
Select Drug Profiles
Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation
Loretta Fala
Web Exclusives
in
Select Drug Profiles
Yonsa (Fine-Particle Abiraterone Acetate) New Formulation Approved for Metastatic Prostate Cancer
Loretta Fala
Web Exclusives
in
Select Drug Profiles
Nuzyra (Omadacycline) Approved for the Treatment of Community-Acquired Bacterial Pneumonia or Acute Bacterial Skin and Skin Structure Infections
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Olumiant (Baricitinib) Once-Daily Oral Drug Approved for the Treatment of Patients with Moderately to Severely Active Rheumatoid Arthritis
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Ilumya (Tildrakizumab-asmn), Interleukin-23 Antagonist, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Tosymra (Sumatriptan) Nasal Spray Approved for the Acute Treatment of Migraine, with or without Aura
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Payers' Guide
,
Select Drug Profiles
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Xeljanz (Tofacitinib) Receives Expanded Indication, Becoming the First Oral JAK Inhibitor Approved for Ulcerative Colitis
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Idhifa (Enasidenib), First-in-Class IDH2 Inhibitor, Approved for Relapsed Acute Myeloid Leukemia with IDH2 Mutation
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Gocovri (Amantadine) First Drug Approved for Dyskinesia in Patients with Parkinson’s Disease
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Xeljanz/Xeljanz XR (Tofacitinib/Tofacitinib XR), an Oral JAK Inhibitor, Now Approved for Adults with Active Psoriatic Arthritis
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Xadago (Safinamide), an Oral MAO-B Inhibitor, FDA Approved as Adjunctive Treatment for Patients with Parkinson’s Disease
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Kevzara (Sarilumab), a New IL-6 Receptor Antagonist, Approved for Active Rheumatoid Arthritis
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Gazyva (Obinutuzumab) Approved for Patients with Rituximab-Refractory Follicular Lymphoma
Loretta Fala
March 2017, Vol 10, Eighth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala
March 2017, Vol 10, Eighth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes
Loretta Fala
March 2017, Vol 10, Eighth Annual Payers' Guide
in
Select Drug Profiles
,
Payers' Guide
Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Odomzo (Sonidegib), a Hedgehog Pathway Inhibitor, FDA Approved for the Treatment of Patients with Locally Advanced Basal-Cell Carcinoma
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Iressa (Gefitinib), Oral Tyrosine Kinase Inhibitor, Approved for First-Line Therapy for Patients with Metastatic NSCLC and EGFR Mutation
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Cotellic (Cobimetinib) FDA Approved as Part of a Combination for Patients with Advanced Melanoma and a BRAF Mutation
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Toujeo (Insulin Glargine) U-300 Approved to Improve Glycemic Control in Adults with Type 1 and Type 2 Diabetes
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Finacia Foam (Azelaic Acid) the Newest Topical Treatment FDA Approved for the Treatment of Inflammatory Lesions of Rosacea
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Drug Updates
,
FDA Approvals
,
Payers' Guide
Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Drug Updates
,
FDA Approvals
,
Payers' Guide
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Drug Updates
,
FDA Approvals
,
Payers' Guide
Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Drug Updates
,
FDA Approvals
,
Payers' Guide
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Drug Updates
,
FDA Approvals
,
Payers' Guide
Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Drug Updates
,
FDA Approvals
,
Payers' Guide
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure
Loretta Fala
September 2015 Vol 8, No 6
in
Drug Updates
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Loretta Fala
Web Exclusives
in
Drug Updates
Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin- Structure Infections
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Drug Updates
,
Payers' Guide
Amitiza (Lubiprostone): The First Oral Treatment Approved by the FDA for Opioid-Induced Constipation
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Botox (OnabotulinumtoxinA) Now FDA Approved for Overactive Bladder
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Breo Ellipta (Fluticasone Furoate/Vilanterol): Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Brintellix Tablets (Vortioxetine) Approved by the FDA for the Treatment of Major Depressive Disorder
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Fetzima Extended-Release (Levomilnacipran) Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Latuda (Lurasidone HCl) Receives 2 New Indications for Use in Bipolar Depression as Monotherapy and as Adjunctive Therapy with Lithium or Valproate
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Simbrinza (Brinzolamide/Brimonidine Tartrate) Receives FDA Approval for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Simponi (Golimumab) Receives New FDA Indication as the First Subcutaneous Anti-TNF Therapy for Ulcerative Colitis
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Simponi Aria (Golimumab): A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Stelara (Ustekinumab) Receives New FDA Indication for the Treatment of Patients with Active Psoriatic Arthritis
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Tecfidera (Dimethyl Fumarate), a New Oral Therapy Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Xiaflex (Collagenase Clostridium Histolyticum), First Drug Approved by the FDA for Peyronie’s Disease
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Brintellix (Vortioxetine) Receives FDA Approval for the Treatment of Major Depressive Disorder
Loretta Fala
Web Exclusives
in
FDA Approvals
,
Select Drug Profiles
Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia
Loretta Fala
Web Exclusives
in
FDA Approvals
,
Select Drug Profiles
Fetzima Extended-Release Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults
Loretta Fala
Web Exclusives
in
FDA Approvals
,
Select Drug Profiles
Simponi Aria: A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Loretta Fala
Web Exclusives
in
FDA Approvals
,
Select Drug Profiles
Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea
Loretta Fala
Payer Perspectives in Dermatology
in
Rosacea
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Loretta Fala
August 2013, Vol 6 ADA 2013 Highlights
in
Drug Updates
Breo Ellipta: A Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD
Loretta Fala
Web Exclusives
in
FDA Approvals
,
Select Drug Profiles
Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Web Exclusives
in
FDA Approvals
,
Select Drug Profiles
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Web Exclusives
in
FDA Approvals
,
Select Drug Profiles
Simbrinza (Brinzolamide/Brimonidine Tartrate) Receives FDA Approval for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
Loretta Fala
Web Exclusives
in
FDA Approvals
,
Select Drug Profiles
Zytiga Receives an Expanded Indication for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Select Drug Profiles
,
Payers' Guide
Zioptan Receives FDA Approval for Patients with Open-Angle Glaucoma and/or Ocular Hypertension
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Select Drug Profiles
,
Payers' Guide
Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Select Drug Profiles
,
Payers' Guide
Tudorza Pressair: A Novel Oral Inhalation Therapy for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease–Associated Bronchospasm
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Select Drug Profiles
,
Payers' Guide
Vascepa: First EPA-Only Omega-3 Therapy Approved by the FDA for Severe Hypertriglyceridemia
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Select Drug Profiles
,
Payers' Guide
Eliquis Approved by the FDA to Reduce the Risks of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Select Drug Profiles
,
Payers' Guide
Last modified: August 13, 2019
SUBSCRIBE
HOME
ABOUT
CONTACT US
TERMS OF USE
PRIVACY POLICY
ADVERTISING POLICY
© Amplity Health. All rights reserved.
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
AHDB
Print Edition
AHDB
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
AHDB
's
Privacy Policy
, and
AHDB
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION
